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Abstract: Breast cancer is the most common cancer in women worldwide. Triple-negative breast cancer patients 
have higher metastatic rate than patients with other breast cancer subtypes. Distant metastasis is one of the 
causes leading to the high mortality rates. Cyclooxygenase-2 (COX2) is associated with breast cancer metastasis 
and the downstream prostaglandin E2 (PGE2) exerted its effect through EP receptors (EP1-EP4). However, the exact 
molecular events of EP receptors in breast cancer metastasis remain undefined. Expressions of EP receptors were 
determined during cancer development in NOD-SCID mice inoculated with MB-231 and MB-231-EP2 clone. EP2 
overexpressing stable clone was constructed to investigate the proliferation and invasion potentials in vivo and in 
vitro. Drug transporter array was used to identify EP2 receptor-associated drug transported genes in breast cancer 
metastasis. Localization of EP2 receptor in primary tissues and xenografts were examined by immunostaining. 
Stable EP2-expression cells formed larger tumors than parental cells in mice model and was highly expressed in 
both primary and metastatic tissues. Silencing of EP2 receptor by siRNA and antagonist (AH 6809) significantly 
decreased cell proliferation and invasion, concomitant with reduced MMP-2 and MMP-9 expressions. Results from 
array data showed that expression of SLC19A3 was markedly increased in EP2 siRNA transfected cells. Ectopic 
expression of SLC19A3 retarded cell proliferation, invasion and MMPs expressions. Notably, SLC19A3 had a lower 
expression in primary tissues and was negatively correlated with EP2 receptor expression. Our novel finding re-
vealed that EP2 receptor regulated metastasis through downregulation of SLC19A3. Thus, targeting EP2-SLC19A3 
signaling is a potential therapeutic therapy for treating metastatic breast cancer.
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Introduction
Breast cancer is the leading cancer and se- 
cond most common cause of death in women. 
According to the GLOBOCAN statistics from the 
World Health Organization, approximately 1.67 
million women were diagnosed with breast can-
cer in 2012 (Globocan 2012, http://globocan.
iarc.fr/Pages/fact_sheets_cancer.aspx). About 
5-10% of breast cancers are metastatic at diag-
nosis and up to 70% of breast cancer involving 
lymph nodes will relapse [1]. Surgery is the 
mainstay treatment of breast cancer while hor-
monal therapy, chemotherapy, targeted thera-
py and/or radiation therapy are given based 
on the tumor grade and molecular subtypes. 
Triple-negative breast cancer (TNBC) is the 
most aggressive molecular subtype that associ-
ates with poor prognosis and high recurrence 
rate. The recurrence rate of TNBC patients is 
approximately 34%, which is 10% higher than 
other molecular subtypes [2]. The survival rate 
after first diagnosis of distant metastasis is 
also shorter when compared with other sub-
types [3]. Due to the lack of expression of estro-
gen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 
(HER2), standard neoadjuvant and prophylactic 
treatments of advanced TNBC are limited to 
chemotherapy only. In addition, TNBC is associ-
ated with germline mutations in BRCA1 and 
BRCA2 and tends to arise in young women [4]. 
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Therefore, understanding the molecular basis 
of metastatic breast cancer, better therapeutic 
strategies and novel prognostic markers can 
be developed to improve the clinical outcome.
Epithelial-mesenchymal transition (EMT) is a 
key process during embryonic development, as 
well as pathological conditions such as cancer 
development and cancer metastasis. Epithelial 
cells increase motility and reduce intercellular 
adhesion during morphological transition to 
mesenchymal cells [5]. Similarly, invasive and 
metastatic behaviours of tumor cells are en- 
hanced by EMT pathways and are associated 
with poor prognosis [5]. Eicosanoid metabolism 
and signaling have been extensively studied in 
the past decade and the roles of cyclooxygen-
ase-2 (COX-2) during tumorigenesis and metas-
tasis have been identified [6, 7]. COX-2 inhibi-
tors have shown promising anti-tumor effect, 
however, the unwanted side effects could not 
be ignored. Hence, it is important to look for 
alternative therapeutic agents for breast can-
cers. Prostaglandin E2 (PGE2) is one of the 
downstream products of COX-2 and exerted its 
effect through EP receptors [6]. Under normal 
condition, PGE2 regulates angiogenesis and 
other signaling pathways by binding to one of 
the EP receptors, namely, EP1- EP4, and each 
receptor has distinct biochemical functions 
[8, 9]. PGE2 promotes angiogenesis and cell 
proliferation during tumorigenesis by inhibiting 
apoptosis [10]. Elevated level of PGE2 has been 
reported in metastatic breast cancer patients 
[11]. Expressions of EP2 and EP4 receptors 
were induced in proliferating mammary gland 
during pregnancy and lactation [12]. Silence 
of EP2 and EP4 receptors suppressed CCR7 
expression and lymph node metastasis [13]. 
Both EP2 and EP4 receptors coupled to the 
activation of adenylate cyclase and the stimu- 
lation of cAMP formation, the amino acid se- 
quences of these two receptors share less than 
40% identity [9, 14]. Low expression of EP1 
receptor has been shown to correlate with 
breast cancer metastasis and poor overall sur-
vival [15]. Recently, COX-2 induced EP4 recep-
tor regulated stem-like cell properties in breast 
carcinogenesis [16, 17]. These studies suggest 
EP receptors play important roles in tumorigen-
esis and metastasis [12].
Matrix metalloproteinases (MMPs) are proteo-
lytic enzymes that degrade extracellular matrix 
[18]. Overexpression of MMP-2 and MMP-9 
have been reported in breast and prostate can-
cer and are positively correlated with COX-2 sig-
naling pathway [19, 20]. Human ATP-binding 
cassette (ABC) transporter family and solute-
carrier (SLC) gene superfamily are critical trans-
porters during chemotherapeutic treatments 
[21, 22]. Chemoresistance in tumor cells are 
associated with decreased intracellular drug 
permeability in ABC proteins, including breast 
cancer resistance protein (BCRP), multidrug 
resistance proteins (MRPs) and P-glycoprotein 
(P-gp) [23]. Extensive research has shown the 
importance of ABC proteins during tumorigen-
esis [19], however, the role of SLC transporters 
is not well characterized. SLC19A3 belongs to 
solute carrier family 19 that codes for thiamine 
transporter-2, and downregulation of SLC19A3 
expression was seen in primary breast cancer 
tissues [24]. Our group was the first to delin-
eate the low expression of SLC19A3 in was due 
to promoter methylation, which could be detect-
ed in plasma of breast cancer patients. To this 
end, the connection between EP2 receptor and 
SLC19A3 in breast cancer metastasis is largely 
unknown.
The aims of this study were to identify the role 
of EP receptors during breast cancer metasta-
sis and the regulation of EMT genes in vivo and 
in vitro. Also, the effect of SLC19A3 on EMT 
modulation and the clinical association with 
the patients’ outcome will be assessed.
Materials and methods
Patient recruitment
This study was approved by Institutional Review 
Board of the University of Hong Kong/Hospital 
Authority Hong Kong West Cluster. Breast can-
cer patients with no previous treatment history 
of any cancer were eligible to join this study. 
Patients with breast cancer were recruited from 
the Department of Surgery, Queen Mary Hos- 
pital and Tung Wah Hospital from 2008 to 
2013. Study-related information was explained 
to each subject and signed consents were 
obtained from all recruited subjects before join-
ing the study. Tumor samples were extracted 
during surgical operation.
Cell lines
Human metastatic TNBC cell line (MDA-MB- 
231, American Type Culture Collection, Roche- 
ville, MD, USA) was used as parental cell line 
in this study. We constructed an EP2-overex- 
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pressing cells, MB-231-EP2 clone. Breast can-
cer cells were cultured in RPMI 1640 medium 
(Gibco, Life technologies, Carlsbad, CA, USA) 
supplemented with 10% heat inactivated fetal 
bovine serum and 1% antibiotic-antimycotic 
(Gibco) at 37°C in a humidified atmosphere 
containing 5% carbon dioxide. Cells were trans-
fected using Qiagen HiPerFect Transfection 
Reagent (Qiagen, Hilden, Germany) according 
to manufacturer’s recommendation. Expres- 
sion of EP receptors was assessed by real-time 
PCR followed by agarose gel electrophoresis.
Tumorigenicity
Human xenograft breast cancer models were 
used to study the expression of EP receptors, 
tumor proliferation and tumor invasion. This 
study was approved by the Committee on the 
Use of Live Animals in Teaching and Research 
(CULATR) in the University of Hong Kong. Cells 
(MB-231 and MB-231-EP2 clone) were trypsin-
ized and the final cell concentration was adjust-
ed to 1 × 106 cells/ml. One hundred microliters 
of cell suspension were injected into the mam-
mary fat pad of nude mice. Xenografted tumor 
size was assessed by external caliper weekly 
and was calculated by using formula V = L × 
W2/2 where V = tumor volume, L = tumor length 
and W = tumor width [25]. Mice were sacrificed 
after 1 week, 2 weeks, 3 weeks, or 3 months 
and inoculated tumors were extracted for histo-
logical examination.
Tumor metastatic animal model
NOD/SCID mice, 4-6 weeks old, were implant-
ed with MB-231 cells stably express luciferase 
gene in a human breast cancer metastasis 
model. Briefly, 100 µl of cell suspension (2 × 
106 cells) was injected into the mammary fat 
pad of mice. These were divided into two groups 
of eight each: (i) MB-231 and (ii) MB-231-EP2 
clone. Tumor growth and metastasis were mon-
itored at regular intervals using in vivo fluores-
cence imaging system (Xenogen100). After 3 
months, the tumors were harvested and col-
lected for further analysis.
Immunohistochemistry
Expressions of EP receptors in primary and 
metastatic tumors were assessed by immunos-
taining using established protocol with modifi-
cation. Briefly, xenografted tissue was fixed 
embedded in paraffin. Tumor was sectioned at 
6 μm and was dewaxed and rehydrated by 
serially immersed in ethanol. Sections were 
quenched with 3% hydrogen peroxide and 
treated with 10 mM sodium citrate. Blocking 
solution was applied for one hour to block the 
non-specific binding sites. Sections were incu-
bated with monoclonal primary antibody target-
ing EP1-4 receptors (1:1000 dilutions, Cayman, 
Michigan, USA) overnight at 4°C. After washing, 
sections were incubated with secondary anti-
body for 30 minutes. Sections were visualized 
using Nikon Eclipse 80i (Nikon, Tokyo, Japan) 
using iView DAB detection kit (Ventana, Arizona, 
USA) and photographs were taken with Spot 
Advanced software.
Cell proliferation
Cell proliferation was studied using the 3- 
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide (MTT) tetrazolium reduction assay. 
Cells were seeded at 96-well plate and were 
treated with 20 nM and 40 nM of EP2-siRNA 
and control siRNA (Qiagen) for 3 days. Culture 
medium was removed and 3% MTT in serum 
free medium was added to each well and fur-
ther incubated for 2 hours. Medium was dis-
carded and dimethyl sulfoxide (DMSO) was 
added and incubated at room temperature 
for 30 minutes. Absorbance at 570 nm was 
measured using a Multiskan FC Microplate 
Photometer (Thermo Scientific, Florida, USA) 
and average absorbance was calculated for 
statistical analysis.
Cell invasion assay
Invasion potential was assessed using Bio Coat 
Matrigel Invasion Chamber (BD Biosciences) 
according to manufacturer’s recommendation. 
After transfection, cells were trypsinized and 
resuspended in serum free medium at a con-
centration of 1 × 104 cells/ml. Resuspended 
cells were placed in the upper chamber and 
complete medium was added to the bottom 
chamber. Cells were incubated and quantified 
after 24 hours. Non-invasive cells were re- 
moved and invasive cells were quantified under 
microscope at 100 × magnification after stain- 
ed with crystal violet. 
Drug transporter array and real-time RT-PCR
Gene expression profiling of MB-231 transfect-
ed with EP2-siRNA and control-siRNA was per-
formed using Drug Transporters RT2 Profiler 
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PCR Array (Qiagen) to identify genes involved 
in the cancer development and metastasis. 
Expressions of EP2 receptor and genes related 
to EMT pathway were confirmed by real-time 
PCR. RNA from primary tissues and cell lines 
were extracted using RNeasy Mini kit (Qiagen) 
and was reversed-transcribed into cDNA using 
a high capacity cDNA reverse transcription kit 
(Applied Biosystems, Foster City, CA, USA). All 
experiments were carried out using Light Cy- 
cler 480 Real-time PCR system (Roche, Basel, 
Switzerland). The expression levels were calcu- 
lated by using comparative threshold cycle (Ct) 
method with formula 2-ΔΔCt. Beta-actin (β-actin) 
or Glyceraldehyde 3-phosphate dehydrogenase 
SPSS, release 20. All P-values are two-sided 
and less than 0.05 was considered statistically 
significant.
Results
EP2 receptor promotes cell proliferation and 
invasion
To investigate the expression levels of EP recep-
tors during cancer development, MB-231 cells 
were injected into mammary fat pad of nude 
mice and examine the expressions of EP1, EP2, 
EP3, and EP4 receptor at different time points 
by real-time RT-PCR. Expressions of EP2 and 
EP4 receptors were significantly induced during 
Figure 1. Effect of EP2 receptors inhibition on cell proliferation and invasion in MB-231 cells. A. Expression levels of 
EP1, EP2, EP3 and EP4 receptors were measured and quantified using RT-PCR after 1 week, 2 weeks, and 3 weeks 
post-injection of MB-231 cells. EP2 receptors were highest among the four receptors. B. Cell proliferation was de-
termined by MTT assay. All experiments were performed in triplicate. C. Cell invasion potential was measured using 
Matrigel Invasion Chamber. D. Expression of MMP-2, MMP-9, and Cyclin D1 were quantified by real-time RT-PCR. 
**P<0.01 and ***P<0.001 are considered as statistically significance.
Table 1. Characteristics of MB-231 and MB-231-EP2 
clone in metastatic breast cancer mice model
Cell line MB-231 (n = 20)
MB-231-EP2 
clone (n = 20)
Number of mice with tumor 10 13
Number of mice had metastatic tumor 6 4
(GAPDH) was used as control to calcu-
late fold changes.
Statistical analysis
Statistical analysis was performed 
using ANOVA or two-tailed student’s 
t test for comparing the means betw- 
een two groups by statistical package 
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Figure 2. Involvement of EP receptors in breast cancer metastasis. A. Mice 
were injected with MB-231 and MB-231-EP2 clone in NOD-SCID mice. Tumor 
volume was measured every 7 days, and metastatic tumors were monitored us-
ing in vivo imaging system. B. Immunostaining of EP receptors were performed 
in primary tumor and metastatic tumor tissues. ***P<0.001 is considered as 
statistically significance.
cancer development when 
compared with EP1 and 
EP3 receptors at 2 weeks 
and 3 weeks post-injection 
(Figure 1A). Higher expres-
sion of EP2 receptor was 
observed in xenografts 3 
weeks after cell inocula-
tion, this suggests that EP2 
receptor contributed in the 
progression of breast can- 
cer.
To validate the functional 
role of EP2 in metastasis, 
cell proliferation and inva-
sion were examined in cells 
transfected with EP2 si- 
RNA. Silence of EP2 re- 
ceptor significantly redu- 
ced cell proliferation and 
invasion dose-dependently 
(Figure 1B and 1C). Expres 
sions of MMP-2, MMP-9, 
and cyclin D1 were down-
regulated in EP2-siRNA 
transfection (Figure 1D).
EP2 promoted EMT and 
metastasis 
A stable EP2-expression 
cell line (MB-231-EP2) was 
used to study tumorigene-
sis and distant metastasis 
in metastatic breast can- 
cer mice model. Cells from 
MB-231 and MB-231-EP2 
clone were injected into the 
mammary fat pad of NOD-
SCID mice. Primary and 
metastatic tumors were 
visualized under in vivo 
imaging system (Xenogen- 
100). Distant metastases, 
including pancreas, lung, 
and liver, were found in 
mice with MB-231 and MB- 
231-EP2 cells. As shown in 
Table 1, a higher tumor fre-
quency was found in mice 
bearing MB-231-EP2 cells. 
Larger tumor volume was 
found in MB-231-EP2 clone 
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than MB-231 (Figure 2A). EP2 receptors were 
predominantly expressed in metastatic tumor 
than in primary tumor (Figure 2B).
To further identify EMT genes involved in metas-
tasis induced by EP2 receptor, we compared 
the gene expression of drug transporter array 
in EP2-siRNA and control-siRNA. Among 84 
genes, there were 17 differentially expressed 
genes in EP2-siRNA transfected cells (Figure 3) 
with a cutoff value of 2-fold difference. As 
shown in Table 2, there were 7 upregulated 
(ABCC10, ABCC2, SLC19A3, SLC22A9, SLC- 
28A1, SLC28A2, and SLC7A8) and 10 down-
regulated (ABCC5, ABCG2, SLC16A3, SLC29A1, 
SLC31A1, SLC3A1, SLC7A11, SLCO1B1, SLCO- 
2A1 and SLCO4A1) genes in EP2-siRNA trans-
fected cells. Significant increase in SLC19A3 
expression was seen in EP2-siRNA when com-
pared with control siRNA, which was compara-
ble with the array data (Figure 5A). This result 
pointed to the importance of EP2 receptor in 
the regulation of SLC19A3. 
Tumor suppressive role of SLC19A3 in cell pro-
liferation and cell invasion
To examine the role of SLC19A3 during tumori-
genesis and metastasis, cells were transfected 
with pcDNA3.1(+) or pcDNA3.1(+) with SLC1- 
9A3 insert to test the effect on cell proliferat- 
19A3 and EP2 receptor, expression of SLC19A3 
will be evaluated in cells transfected with EP2-
siRNA and EP2 antagonist (AH6809). Silencing 
of EP2 receptor significantly restored the ex- 
pression of SLC19A3 (Figure 5A). The expres-
sion of SLC19A3 was lowered in primary tumor 
when compared with adjacent non-tumor tis-
sues (Figure 5B). Our results indicated that 
expression of EP2 receptor was inversely cor-
related to the level of SLC19A3 in tumor tissues 
(Figure 5C).
Discussion
Metastasis is one of the major factors that lead 
to poor prognosis in breast cancer patients, 
especially in patients with TNBC subtype. TNBC 
is associated with poor prognosis with limited 
therapeutic options, resulting in high recur-
rence rate and metastatic rate than other 
breast cancer subtypes [26]. Previous studies 
have shown that TNBC patients with residual 
diseases after treated with neoadjuvant che-
motherapy showed poor 3-year overall survival 
rate when compared with non-TNBC patients 
[27]. To this end, understanding the molecular 
mechanism of metastasis may help to design 
better drugs to prevent or treat metastasis.
EP receptors have been studied extensively 
due to its association with cancer development 
Figure 3. Drug transporter gene expression profiling of control-siRNA and EP2-
siRNA treated MB-231 cells.
ion assay and invasion. 
Ectopic expression of SL- 
C19A3 remarkably sup-
pressed cell proliferation 
relative to cells without 
SLC19A3 insert (Figure 
4A). Also, cell invasion as- 
say showed that the num-
ber of invaded cells was 
reduced in SLC19A3-over- 
expressing cells than emp- 
ty vector (Figure 4B). Im- 
portantly, EMT-related gen- 
es, MMP-2 and MMP-9, 
were suppressed by SLC- 
19A3 overexpression (Fig- 
ure 4C).
Expression of SLC19A3 is 
inversely correlated with 
EP2 receptor
To further investigate the 
correlation between SLC- 
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and metastasis in cancers of colon, lung, pros-
tate and skin [20, 28]. While there are four EP 
coupling receptors mediating PGE2 signaling, 
our data suggested that overexpression of EP2 
receptor increased cell proliferation and inva-
sion during tumorigenesis and EP2 receptor 
were also responsible for developing distant 
metastasis for TNBC in animal models. Previous 
studies have shown that EP2 and EP4 recep-
tors are predominantly expressed in mammary 
Table 2. Differential expression of drug transporter genes in EP2 siRNA cells
Symbol Fold change Full name
ABCC10 2.0491 ATP-binding cassette, sub-family C (CFTR/MRP), member 10
ABCC2 2.1214 ATP-binding cassette, sub-family C (CFTR/MRP), member 2
SLC19A3 32.5594 Solute carrier family 19 (thiamine transporter), member 3
SLC22A9 3.7581 Solute carrier family 22 (organic anion transporter), member 9
SLC28A1 2.2191 Solute carrier family 28 (concentrative nucleoside transporter), member 1
SLC28A2 3.1167 Solute carrier family 28 (concentrative nucleoside transporter), member 2
SLC7A8 3.1932 Solute carrier family 7 (amino acid transporter light chain, L system), member 8
ABCC5 -6.0419 ATP-binding cassette, sub-family C (CFTR/MRP), member 5
ABCG2 -4.5473 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)
SLC16A3 -2.4538 Solute carrier family 16 (monocarboxylate transporter), member 3
SLC29A1 -16.1113 Solute carrier family 29 (equilibrative nucleoside transporter), member 1
SLC31A1 -2.4623 Solute carrier family 31 (copper transporter), member 1
SLC3A1 -3.2154 Solute carrier family 3 (amino acid transporter heavy chain), member 1
SLC7A11 -2.0705 Solute carrier family 7 (anionic amino acid transporter light chain, xc-system), member 11
SLCO1B1 -6.0629 Solute carrier organic anion transporter family, member 1B1
SLCO2A1 -3.3519 Solute carrier organic anion transporter family, member 2A1
SLCO4A1 -3.3288 Solute carrier organic anion transporter family, member 4A1
RNA was extracted from control-siRNA and EP2-siRNA treated MB-231 cells. Expression levels of 84 genes were analyzed using 
drug transporter array. Only genes that were upregulated or downregulated by at least 2-fold are listed.
Figure 4. Effect of SLC19A3 on cell prolif-
eration and invasion in MB-231 cells. A. Cell 
proliferation was measured by MTT assay. 
B. Cell invasion potential was measured by 
MTT. C. Expressions of MMP-2 and MMP-
9 were measured by real-time RT-PCR. 
*P<0.05 and **P<0.01 are considered sta-
tistically significance.
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tumors [12]. Several lines of evidence reported 
that EP2 and EP4 receptors had a positive cor-
relation with increased breast cancer metasta-
sis [12, 13, 17, 29-32]. EP2 receptor was found 
to be strongly induced in mammary adenoma 
cells [12]. Moreover, breast cancer metastasis 
was inhibited by antagonizing EP4 receptor 
[29]. Cancer stem cells have been demonstrat-
ed with their ability to promote cancer metasta-
sis [33], and expression of EP4 receptor has 
been associated with inhibition of breast can-
cer stem-cell properties [17]. EP2 receptor 
increased tumor proliferation and tumor inva-
siveness in the present study. The effect of EP2 
receptor on cell proliferation and invasiveness 
was validated and confirmed by EP2-siRNA 
knockdown in vitro. This reduction in cell prolif-
eration and invasion suggested that EP2 recep-
tor play an important role during cancer pro-
gression, which was in line with previous study 
[12]. Our data indicated that EP2 receptor 
had the strongest expression among other EP 
receptors during cancer development. In addi-
tion, EP2 receptor was not only predominantly 
expressed in mammary tumor, but also ex- 
pressed in metastatic tumors in this study. 
Moreover, average tumor volume was larger 
with a higher percentage of mice implanted 
with EP2 clone developed tumor compared to 
MB-231, suggesting the invasive nature of EP2 
receptor during cancer development. Although 
there were fewer mice with distant metastasis 
in mice-bearing EP2 clone, these mice had a 
poor survival rate than mice with MB-231 with-
in the experimental period, which result in lower 
metastasis frequency in mice with EP2-clone.
The association between COX-2 and MMPs has 
been demonstrated in many cancers [19, 20]. 
High expression level of EP2 receptor in meta-
static tissues with increased cell proliferation 
and invasion capacities implicated a possible 
correlation between EP2 receptor and MMP-2 
and MMP-9. MMPs are classified into collage-
nases, gelatinases, stromelysin, matrilysin and 
the membrane-type MMP [34]. The increased 
MMPs induced by EP2 receptor during tumori-
genesis would facilitate the process of angio-
genesis and cell migration. Degradation of 
basement membrane by MMP-2 and MMP-9 
enhanced the migration potential of cancer 
cells leading to tumor spread [34]. High expres-
sion of MMP-9 was associated with TNBC and 
higher chance of nodal and distant metastasis 
[18]. On the other hand, cyclin D1 is one of the 
common genes that overexpressed in breast 
tumors which involved in cell cycle progression 
[35].
Chemosensitivity and resistance in tumor cells 
are contributed by the variation of membrane 
transporters’ activities [36]. Low expression of 
Figure 5. A. Effect of EP2 siRNA or antagonist in 
EMT-related genes. B. Expression of SLC19A3 in 
human primary tissues. C. A negative correlation 
between EP2 receptor and SLC19A3 expression in 
paired primary tissues (n = 12). *P<0.05 is con-
sidered statistically significance.
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SLC19A3 in primary breast tumor tissue was 
seen, which was consistent with our earlier 
finding in the plasma of breast cancer patients 
[20]. Expression of SLC19A3 was restored by 
suppressing EP2 receptor through siRNA and 
EP2 antagonist, suggested that expression 
of SLC19A3 was regulated by EP2 receptor. 
Downregulation of SLC19A3 in breast, lung 
and gastric cancers has been reported [37-39]. 
SLC19A3 was downregulated in breast cancer 
by hypermethylation of CpG region in the pro-
moter [24]. Similar findings on SLC19A3 down-
regulation by DNA methylation and histone 
deacetylation in colon cancer cell lines have 
also been reported [40]. In contrast, upregula-
tion of SLC19A3 in breast cancer cell lines was 
found under hypoxic condition [23]. The dis-
crepancy may due to variations in the use of 
different types of breast cancer cell lines and 
experimental methods. Since breast cancer is 
a heterogeneous disease that may explain 
the variations in expression levels in different 
breast cancer subtypes. Further studies are 
warranted to investigate the change of SLC- 
19A3 expression under different conditions in 
various breast cancer subtypes.
This is the first study to demonstrate a negat- 
ive correlation between EP2 receptor and SLC- 
19A3 in breast cancer progression and metas-
tasis. The current study proposed a pathway 
tor as the standard therapeutic treatments 
[43]. Results from this study provide the basis 
for the development of blocking EP2/SLC19A3 
signaling pathway as alternative treatment for 
breast cancer metastasis.
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